Should I buy or sell NewAmsterdam Pharma stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NAMS shares. View NAMS analyst ratings or view top-rated stocks .

What is NewAmsterdam Pharma's stock price target for 2024?

5 equities research analysts have issued 12 month price objectives for NewAmsterdam Pharma's stock. Their NAMS share price targets range from $30.00 to $37.00. On average, they predict the company's share price to reach $33.25 in the next year. This suggests a possible upside of 66.8% from the stock's current price. View analysts price targets for NAMS or view top-rated stocks among Wall Street analysts .

How have NAMS shares performed in 2024?

NewAmsterdam Pharma's stock was trading at $11.17 at the start of the year. Since then, NAMS shares have increased by 78.4% and is now trading at $19.93. View the best growth stocks for 2024 here .

When is NewAmsterdam Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our NAMS earnings forecast .

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Yarbrough Capital LLC (0.03%). Insiders that own company stock include James N Topper, Johannes Jacob Piete Kastelein and Louis G Lange. View institutional ownership trends .

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free NAMS Stock Alerts

$19.93

+0.49 (+2.52%)

(As of 04/19/2024 ET)

Compare

Today's Range: $19.21
▼
$20.32
50-Day Range: $18.95
▼
$24.23
52-Week Range: $5.63
▼
$26.35

Volume: 140,271 shs
Average Volume: 245,384 shs
Market Capitalization: $1.78 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.25

Get NewAmsterdam Pharma alerts:

NewAmsterdam Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 66.8% Upside
$33.25 Price Target
Short Interest: Healthy
0.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 2 Articles This Week
Insider Trading: Selling Shares
$4.10 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.89) to ($1.26) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.22 out of 5 stars

Medical Sector

312th out of 911 stocks

Pharmaceutical Preparations Industry

133rd out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
NewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
NewAmsterdam Pharma has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.86% of the float of NewAmsterdam Pharma has been sold short.
Short Interest Ratio / Days to Cover
NewAmsterdam Pharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NewAmsterdam Pharma has recently decreased by 1.94%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
NewAmsterdam Pharma does not currently pay a dividend.
Dividend Growth
NewAmsterdam Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NAMS.

2.8

News and Social Media Coverage

News Sentiment
NewAmsterdam Pharma has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for NewAmsterdam Pharma this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NAMS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NewAmsterdam Pharma insiders have sold 1,382.58% more of their company's stock than they have bought. Specifically, they have bought $276,224.00 in company stock and sold $4,095,234.00 in company stock.
Percentage Held by Insiders
Only 2.50% of the stock of NewAmsterdam Pharma is held by insiders.
Percentage Held by Institutions
89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.89) to ($1.26) per share.
Price to Book Value per Share Ratio
NewAmsterdam Pharma has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NAMS Stock News Headlines

March 29, 2024 | insidertrades.com

NewAmsterdam Pharma (NASDAQ:NAMS) Director Acquires $181,223.50 in Stock

March 29, 2024 | insidertrades.com

NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $4,095,234.00 in Stock

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 9, 2024 | globenewswire.com

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

April 9, 2024 | businesswire.com

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

April 2, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)

April 1, 2024 | globenewswire.com

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

March 28, 2024 | msn.com

If you loved NBC's ER, this new Max medical drama is the show for you

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 25, 2024 | globenewswire.com

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

March 19, 2024 | seekingalpha.com

NAMS NewAmsterdam Pharma Company N.V.

March 13, 2024 | msn.com

Amring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic Acquisition

March 12, 2024 | globenewswire.com

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

March 1, 2024 | finance.yahoo.com

NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations

February 28, 2024 | finanznachrichten.de

NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024 | finance.yahoo.com

NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress

February 28, 2024 | globenewswire.com

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for NewAmsterdam Pharma with Increased Price Target Amid Promising Drug Trials and Strategic Initiatives

February 26, 2024 | finance.yahoo.com

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

February 24, 2024 | msn.com

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11

February 23, 2024 | benzinga.com

NewAmsterdam Pharma Stock (NASDAQ:NAMS), Insider Trading Activity

February 20, 2024 | msn.com

List of Universities that offer pharmacy in South Africa in 2024

February 16, 2024 | finanznachrichten.de

NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

February 14, 2024 | seekingalpha.com

NewAmsterdam Pharma prices $175M share offering

February 14, 2024 | finance.yahoo.com

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

February 13, 2024 | globenewswire.com

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

February 13, 2024 | finance.yahoo.com

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

See More Headlines

Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NAMS
CUSIP: N/A
CIK: 1936258
Web: www.newamsterdampharma.com
Phone: 352062971
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.25
High Stock Price Target: $37.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +71.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.95
Quick Ratio: 6.95

Sales & Book Value

Annual Sales: $14.09 million
Price / Sales: 123.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.50 per share
Price / Book: 5.55

Miscellaneous

Outstanding Shares: 89,270,000
Free Float: 87,035,000
Market Cap: $1.74 billion
Optionable: Not Optionable
Beta: 0.02

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Michael Harvey Davidson FACC (Age 68)
Facp., M.D., CEO, President, Executive Board Member & Director
Comp: $882k
Dr. Johannes Jacob Pieter Kastelein FESC (Age 70)
M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director
Comp: $677.76k
Mr. Mayur Amrat Somaiya (Age 51)
Chief Financial Officer
Comp: $130.58k
Mr. Douglas F. Kling (Age 51)
Chief Operating Officer
Mr. Jim Jacobson
Chief Legal Officer & Secretary
Dr. Marc Ditmarsch M.D. (Age 57)
Chief Development Officer
Dr. Sheng Cui Ph.D.
VP & Head of Chemistry Manufacturing and Controls (CMC)
Ms. Annie Neild
VP & Head of Regulatory Affairs
Mr. William Jones Jr. (Age 60)
M.B.A., Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NAMS Stock Analysis - Frequently Asked Questions

Should I buy or sell NewAmsterdam Pharma stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NAMS shares.
View NAMS analyst ratings or view top-rated stocks.
What is NewAmsterdam Pharma's stock price target for 2024?: 5 equities research analysts have issued 12 month price objectives for NewAmsterdam Pharma's stock. Their NAMS share price targets range from $30.00 to $37.00. On average, they predict the company's share price to reach $33.25 in the next year. This suggests a possible upside of 66.8% from the stock's current price.
View analysts price targets for NAMS or view top-rated stocks among Wall Street analysts.
How have NAMS shares performed in 2024?: NewAmsterdam Pharma's stock was trading at $11.17 at the start of the year. Since then, NAMS shares have increased by 78.4% and is now trading at $19.93.
View the best growth stocks for 2024 here.
When is NewAmsterdam Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our NAMS earnings forecast.

Who are NewAmsterdam Pharma's major shareholders?: NewAmsterdam Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Yarbrough Capital LLC (0.03%). Insiders that own company stock include James N Topper, Johannes Jacob Piete Kastelein and Louis G Lange.
View institutional ownership trends.
How do I buy shares of NewAmsterdam Pharma?: Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAMS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial